Market News & Trends
Vyant Bio & OrganoTherapeutics Announce Strategic Collaboration
Vyant Bio, Inc. and OrganoTherapeutics recently announced they have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of….
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development
Qualigen Therapeutics, Inc. recently announced it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of lead…
Mapi Pharma Receives US Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive MS With a Sustained-Release Glatiramer Acetate Depot
Mapi Pharma Ltd. recently announced it has been granted US Patent No. 11,167,003 titled Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis….
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial for Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause
Acer Therapeutics Inc. recently announced the enrollment of the first patient in its Phase 2a randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy, safety, and…
Owen Mumford & Noble International Announce Collaboration
Owen Mumford Pharmaceutical Services recently announces its alliance with Noble International, an Aptar Pharma company and world leader in providing drug delivery….
Rentschler Biopharma & Vetter Unveil Xpert Alliance, a Joint Visualization of their Successful Strategic Collaboration
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations (CDMOs), recently announced they are unveiling Xpert Alliance, a joint visualization of their…
eTheRNA Manufacturing Announces New LNP Formulation Development & Production Service
eTheRNA Manufacturing recently introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early preclinical development of RNA-based….
Artizan Biosciences Announces Issuance of New US Patent to Cover Proprietary Discovery Platform
Artizan Biosciences, Inc. recently announced the US Patent and Trademark Office has issued US Patent No. 11,299,790 that broadens the use of the company’s proprietary…
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations
Gb Sciences, Inc. recently announced its sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was….
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study
Albireo Pharma, Inc. recently announced the completion of patient enrollment in the ASSERT study, a Phase 3 pivotal trial of Bylvay (odevixibat) in patients with…
Artelo Expands Collaboration With Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein Inhibition in Cancer
Artelo Biosciences, Inc. recently announced it has entered into a second collaboration with Richard K. Porter, PhD, of the School of Biochemistry & Immunology at….
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
Eagle Pharmaceuticals, Inc. recently announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc to Eagle by way of a scheme of arrangement under….
Ionis & Biogen Announce Topline Phase 1 Study Results
Ionis Pharmaceuticals, Inc. & Biogen, Inc. recently announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people…
European Medicines Agency Commences Review of Novel Gene Therapy Candidate for People With Hemophilia B
CSL Behring recently announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez) under its accelerated assessment procedure.…
RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial
RAPT Therapeutics, Inc. recently announced biomarker data from the company’s randomized placebo-controlled Phase 1b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis (AD)…
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Prothena Corporation plc recently announced the US FDA has cleared the investigational new drug (IND) application for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody…
DFE Pharma, Harro Höfliger & Sterling Announce Unique Partnership to Provide Formulation Services for Respiratory Products
Three leading companies in their respective fields – DFE Pharma (excipients solution provider), Harro Höfliger (equipment supplier), and Sterling (API manufacturer) recently announced a unique partnership….
Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
Provectus recently announced it has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal…
Gerresheimer Opens a New Plant to Produce Pharmaceutical Container Solutions
Gerresheimer ceremoniously took over a new building in Berlin, Ohio. In the future, the square plastic containers of the Duma Twist-Off Q brand with a 40-ml filling volume….
4D pharma Announces Positive Interim Results From Phase 1/2 Study
4D pharma plc recently announced that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA(R) (pembrolizumab), in…
